These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34185403)

  • 21. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.
    Suttle AB; Ball HA; Molimard M; Hutson TE; Carpenter C; Rajagopalan D; Lin Y; Swann S; Amado R; Pandite L
    Br J Cancer; 2014 Nov; 111(10):1909-16. PubMed ID: 25349968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study).
    Sepe P; Martinetti A; Mennitto A; Verzoni E; Claps M; Raimondi A; Sottotetti E; Grassi P; Guadalupi V; Stellato M; Zattarin E; Di Maio M; Procopio G
    Am J Clin Oncol; 2020 Sep; 43(9):621-627. PubMed ID: 32889831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
    Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
    Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
    Choueiri TK; Figueroa DJ; Fay AP; Signoretti S; Liu Y; Gagnon R; Deen K; Carpenter C; Benson P; Ho TH; Pandite L; de Souza P; Powles T; Motzer RJ
    Clin Cancer Res; 2015 Mar; 21(5):1071-7. PubMed ID: 25538263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study.
    Masini C; Vitale MG; Maruzzo M; Procopio G; de Giorgi U; Buti S; Rossetti S; Iacovelli R; Atzori F; Cosmai L; Vignani F; Prati G; Scagliarini S; Guida A; Berselli A; Pinto C
    Clin Genitourin Cancer; 2019 Feb; 17(1):e150-e155. PubMed ID: 30396828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
    Liu XD; Hoang A; Zhou L; Kalra S; Yetil A; Sun M; Ding Z; Zhang X; Bai S; German P; Tamboli P; Rao P; Karam JA; Wood C; Matin S; Zurita A; Bex A; Griffioen AW; Gao J; Sharma P; Tannir N; Sircar K; Jonasch E
    Cancer Immunol Res; 2015 Sep; 3(9):1017-29. PubMed ID: 26014097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma.
    Reimers MA; Shango MM; Daignault-Newton S; Dedinsky R; Karsies D; Kraft S; Riddle L; Felton JA; Wen B; Gersch C; Rae JM; Redman BG; Alva AS
    Invest New Drugs; 2019 Apr; 37(2):323-330. PubMed ID: 30393825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.
    Kim MJ; Park SH; Lee JL; Lee SH; Lee SJ; Lim HY
    BMC Urol; 2016 Aug; 16(1):46. PubMed ID: 27484998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma.
    Hirsch L; Flippot R; Escudier B; Albiges L
    Drugs; 2020 Aug; 80(12):1169-1181. PubMed ID: 32601914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.
    Appleman LJ; Kim SE; Harris WB; Pal SK; Pins MR; Kolesar J; Agarwal N; Parikh RA; Vaena DA; Ryan CW; Hashmi M; Costello BA; Cella D; Dutcher JP; DiPaola RS; Haas NB; Wagner LI; Carducci MA
    J Clin Oncol; 2024 Jun; 42(17):2061-2070. PubMed ID: 38531002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
    Mosca A; De Giorgi U; Procopio G; Basso U; Cartenì G; Bersanelli M; Naglieri E; Galli L; Caffo O; Fornarini G; Boccardo F; Porta C
    Jpn J Clin Oncol; 2021 Mar; 51(3):484-491. PubMed ID: 33212499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
    Brotelle T; Bay JO
    Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?
    Erdogan B; Kostek O; Bekir Hacioglu M; Gokyer A; Kucukarda A; Ozcan E; Gokmen I; Uzunoglu S; Cicin I
    J BUON; 2021; 26(5):2196-2201. PubMed ID: 34761635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.
    Zizzari IG; Napoletano C; Botticelli A; Caponnetto S; Calabrò F; Gelibter A; Rughetti A; Ruscito I; Rahimi H; Rossi E; Schinzari G; Marchetti P; Nuti M
    Cancer Immunol Res; 2018 Jun; 6(6):711-722. PubMed ID: 29700053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
    Motzer RJ; Haas NB; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Melichar B; Rini BI; Choueiri TK; Zemanova M; Wood LA; Reaume MN; Stenzl A; Chowdhury S; Lim HY; McDermott R; Michael A; Bao W; Carrasco-Alfonso MJ; Aimone P; Voi M; Doehn C; Russo P; Sternberg CN;
    J Clin Oncol; 2017 Dec; 35(35):3916-3923. PubMed ID: 28902533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
    Poprach A; Fiala O; Chloupkova R; Melichar B; Lakomy R; Petrakova K; Zemanova M; Kopeckova K; Slaby O; Studentova H; Kopecký J; Kiss I; Finek J; Dusek L; Buchler T
    Anticancer Res; 2018 Jan; 38(1):449-456. PubMed ID: 29277808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.